Autopsy Study Defines Composition and Dynamics of the HIV-1 Reservoir after Allogeneic Hematopoietic Stem Cell Transplantation with CCR5Δ32/Δ32 Donor Cells.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI

HIV Infections* ; HIV Seropositivity* ; HIV-1*/genetics ; Hematopoietic Stem Cell Transplantation*; Autopsy ; Humans ; RNA

Allo-HSCT with CCR5Δ32/Δ32 donor cells is the only curative HIV-1 intervention. We investigated the impact of allo-HSCT on the viral reservoir in PBMCs and post-mortem tissue in two patients. IciS-05 and IciS-11 both received a CCR5Δ32/Δ32 allo-HSCT. Before allo-HSCT, ultrasensitive HIV-1 RNA quantification; HIV-1-DNA quantification; co-receptor tropism analysis; deep-sequencing and viral characterization in PBMCs and bone marrow; and post-allo-HSCT, ultrasensitive RNA and HIV-1-DNA quantification were performed. Proviral quantification, deep sequencing, and viral characterization were done in post-mortem tissue samples. Both patients harbored subtype B CCR5-tropic HIV-1 as determined genotypically and functionally by virus culture. Pre-allo-HSCT, HIV-1-DNA could be detected in both patients in bone marrow, PBMCs, and T-cell subsets. Chimerism correlated with detectable HIV-1-DNA LTR copies in cells and tissues. Post-mortem analysis of IciS-05 revealed proviral DNA in all tissue biopsies, but not in PBMCs. In patient IciS-11, who was transplanted twice, no HIV-1-DNA could be detected in PBMCs at the time of death, whereas HIV-1-DNA was detectable in the lymph node. In conclusion, shortly after CCR5Δ32/Δ32, allo-HSCT HIV-1-DNA became undetectable in PBMCs. However, HIV-1-DNA variants identical to those present before transplantation persisted in post-mortem-obtained tissues, indicating that these tissues play an important role as viral reservoirs.

Open Forum Infect Dis. 2018 May 22;5(5):ofy090. (PMID: 29868623)
N Engl J Med. 2009 Feb 12;360(7):692-8. (PMID: 19213682)
Nat Med. 2021 Dec;27(12):2085-2098. (PMID: 34848888)
PLoS Pathog. 2013;9(5):e1003347. (PMID: 23671416)
AIDS. 2007 Mar 30;21(6):776-7. (PMID: 17413704)
Nat Biotechnol. 2007 Dec;25(12):1407-10. (PMID: 18066037)
J Acquir Immune Defic Syndr. 2022 Mar 1;89(3):297-302. (PMID: 34753870)
Clin Infect Dis. 2019 Feb 1;68(4):684-687. (PMID: 30020413)
Nature. 2019 Apr;568(7751):244-248. (PMID: 30836379)
J Neurovirol. 2018 Aug;24(4):439-453. (PMID: 29687407)
J Acquir Immune Defic Syndr. 2017 Jul 1;75(3):328-337. (PMID: 28350553)
N Engl J Med. 2014 Aug 28;371(9):880-2. (PMID: 25162903)
Virology. 1997 Jun 23;233(1):193-8. (PMID: 9201229)
Lancet HIV. 2020 May;7(5):e340-e347. (PMID: 32169158)
Ann Intern Med. 2014 Sep 2;161(5):319-27. (PMID: 25047577)
Mol Biol Evol. 2016 Jul;33(7):1870-4. (PMID: 27004904)
J Clin Invest. 2020 Apr 1;130(4):1699-1712. (PMID: 31910162)
Lancet HIV. 2015 Jun;2(6):e236-42. (PMID: 26423196)
Clin Infect Dis. 2014 Aug 15;59(4):596-600. (PMID: 24759824)
J Int AIDS Soc. 2018 Sep;21(9):e25185. (PMID: 30375818)
Sci Transl Med. 2020 May 6;12(542):. (PMID: 32376772)
Ann Intern Med. 2018 Nov 20;169(10):674-683. (PMID: 30326031)
Science. 1985 Aug 9;229(4713):563-6. (PMID: 2992081)
PLoS Med. 2017 Nov 28;14(11):e1002461. (PMID: 29182633)
Infect Genet Evol. 2013 Oct;19:337-48. (PMID: 23660484)

P30 CA008748 United States CA NCI NIH HHS

Keywords: CCR5Δ32; HIV persistence; HIV-1; allo-HSCT; cure; reservoir; tissue

63231-63-0 (RNA)

Date Created: 20220923 Date Completed: 20220926 Latest Revision: 20221116

20231215

PMC9503691

10.3390/v14092069

36146874